Gómez C, Pozo O J, Fabregat A, Marcos J, Deventer K, Van Eenoo P, Segura J, Ventura R
Bioanalysis Research Group, IMIM, Hospital del Mar, Doctor Aiguader 88, 08003, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003, Barcelona, Spain.
Drug Test Anal. 2012 Oct;4(10):775-85. doi: 10.1002/dta.1433. Epub 2012 Oct 22.
Boldione (1,4-androstadien-3,17-dione) is included in the list of prohibited substances, issued by the World Anti-Doping Agency (WADA). Endogenous production of low concentrations of boldione has also been reported. The objective of this study was to assess boldione metabolism in humans. Detection of boldione metabolites was accomplished by analysis by liquid chromatography coupled to tandem mass spectrometry of urine samples obtained after administration of the drug and subjected to different sample preparation procedures to analyze the different metabolic fractions (free, glucuronides, sulpfates and released in basic media). In addition to boldione, eight metabolites were detected in the free fraction. Four of them were identified by comparison with standards: 6β-hydroxy-boldenone (M3), androsta-1,4,6-triene-3,17-dione (M5), (5α)-1-androstenedione (M6) and (5α)-1-testosterone (M8). Metabolite M7 was identified as the 5β-isomer of 1-androstenedione, and metabolites M1, M2 and M4 were hydroxylated metabolites and tentative structures were proposed based on mass spectrometric data. After β-glucuronidase hydrolysis, five additional metabolites excreted only as conjugates with glucuronic acid were detected: boldenone, (5β)-1-testosterone (M9), and three metabolites resulting from reduction of the 3-keto group. Boldenone, epiboldenone, and hydroxylated metabolites of boldione, boldenone and 1-testosterone were detected as conjugates with sulfate. In addition, boldione and seven metabolites (boldenone, M2, M3, M4, M5, M7 and M9) increased their concentration in urine after treatment of the urine in alkaline conditions. In summary, 15 boldione metabolites were detected in all fractions. The longer detection time was observed for metabolite M4 after alkaline treatment of the urine, which was detected up to 5 days after boldione administration.
宝丹酮(1,4-雄甾二烯-3,17-二酮)被列入世界反兴奋剂机构(WADA)发布的禁用物质清单。也有报道称人体会内源性产生低浓度的宝丹酮。本研究的目的是评估宝丹酮在人体内的代谢情况。通过液相色谱-串联质谱分析给药后采集的尿液样本,并采用不同的样品制备程序来分析不同的代谢组分(游离型、葡萄糖醛酸苷型、硫酸酯型以及在碱性介质中释放的组分),从而实现对宝丹酮代谢物的检测。除了宝丹酮外,在游离组分中还检测到了8种代谢物。其中4种通过与标准品比较得以鉴定:6β-羟基-宝丹酮(M3)、雄甾-1,4,6-三烯-3,17-二酮(M5)、(5α)-1-雄烯二酮(M6)和(5α)-1-睾酮(M8)。代谢物M7被鉴定为1-雄烯二酮的5β-异构体,代谢物M1、M2和M4为羟基化代谢物,并根据质谱数据提出了初步结构。经β-葡萄糖醛酸苷酶水解后,又检测到另外5种仅以葡萄糖醛酸共轭物形式排泄的代谢物:宝丹酮、(5β)-1-睾酮(M9)以及3-酮基还原产生的3种代谢物。宝丹酮、表宝丹酮以及宝丹酮、宝丹酮和1-睾酮的羟基化代谢物被检测为硫酸酯共轭物。此外,尿液经碱性处理后,宝丹酮和7种代谢物(宝丹酮、M2、M3、M4、M5、M7和M9)在尿液中的浓度有所增加。总之,在所有组分中检测到了15种宝丹酮代谢物。尿液经碱性处理后,代谢物M4的检测时间最长,在宝丹酮给药后5天仍能检测到。